• Je něco špatně v tomto záznamu ?

Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

L. Peyrin-Biroulet, P. Arkkila, A. Armuzzi, S. Danese, J. Guardiola, J. Jahnsen, C. Lees, E. Louis, M. Lukáš, W. Reinisch, X. Roblin, M. Jang, HG. Byun, DH. Kim, SJ. Lee, R. Atreya

. 2022 ; 22 (1) : 291. [pub] 20220608

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, metaanalýza, systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018037

BACKGROUND AND AIMS: There are limited comparative data for infliximab and vedolizumab in inflammatory bowel disease patients. METHODS: We conducted a systematic review and meta-analysis to compare the efficacy and safety of infliximab and vedolizumab in adult patients with moderate-to-severe Crohn's disease or ulcerative colitis. RESULTS: We identified six eligible Crohn's disease and seven eligible ulcerative colitis trials that randomised over 1900 participants per disease cohort to infliximab or vedolizumab. In the Crohn's disease and ulcerative colitis cohorts, infliximab yielded better efficacy than vedolizumab for all analysed outcomes (CDAI-70, CDAI-100 responses, and clinical remission for Crohn's disease and clinical response and clinical remission for ulcerative colitis) during the induction phase, with non-overlapping 95% confidence intervals. In the maintenance phase, similar proportions of infliximab- or vedolizumab-treated patients achieved clinical response, clinical remission, or mucosal healing in both Crohn's disease and ulcerative colitis. For the safety outcomes, rates of adverse events, serious adverse events, and discontinuations due to adverse events were similar in infliximab- and vedolizumab-treated patients in both diseases. The infection rate was higher in infliximab for Crohn's disease and higher in vedolizumab when treating patients with ulcerative colitis. There was no difference between the treatments in the proportions of patients who reported serious infections in both indications. CONCLUSIONS: Indirect comparison of infliximab and vedolizumab trials in adult patients with moderate-to severe Crohn's disease or ulcerative colitis demonstrated that infliximab has better efficacy in the induction phase and comparable efficacy during the maintenance phase and overall safety profile compared to vedolizumab.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018037
003      
CZ-PrNML
005      
20220804134522.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s12876-022-02347-1 $2 doi
035    __
$a (PubMed)35676620
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Peyrin-Biroulet, Laurent $u Centre Hospitalier Régional Universitaire de Nancy, Nancy, France
245    10
$a Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis / $c L. Peyrin-Biroulet, P. Arkkila, A. Armuzzi, S. Danese, J. Guardiola, J. Jahnsen, C. Lees, E. Louis, M. Lukáš, W. Reinisch, X. Roblin, M. Jang, HG. Byun, DH. Kim, SJ. Lee, R. Atreya
520    9_
$a BACKGROUND AND AIMS: There are limited comparative data for infliximab and vedolizumab in inflammatory bowel disease patients. METHODS: We conducted a systematic review and meta-analysis to compare the efficacy and safety of infliximab and vedolizumab in adult patients with moderate-to-severe Crohn's disease or ulcerative colitis. RESULTS: We identified six eligible Crohn's disease and seven eligible ulcerative colitis trials that randomised over 1900 participants per disease cohort to infliximab or vedolizumab. In the Crohn's disease and ulcerative colitis cohorts, infliximab yielded better efficacy than vedolizumab for all analysed outcomes (CDAI-70, CDAI-100 responses, and clinical remission for Crohn's disease and clinical response and clinical remission for ulcerative colitis) during the induction phase, with non-overlapping 95% confidence intervals. In the maintenance phase, similar proportions of infliximab- or vedolizumab-treated patients achieved clinical response, clinical remission, or mucosal healing in both Crohn's disease and ulcerative colitis. For the safety outcomes, rates of adverse events, serious adverse events, and discontinuations due to adverse events were similar in infliximab- and vedolizumab-treated patients in both diseases. The infection rate was higher in infliximab for Crohn's disease and higher in vedolizumab when treating patients with ulcerative colitis. There was no difference between the treatments in the proportions of patients who reported serious infections in both indications. CONCLUSIONS: Indirect comparison of infliximab and vedolizumab trials in adult patients with moderate-to severe Crohn's disease or ulcerative colitis demonstrated that infliximab has better efficacy in the induction phase and comparable efficacy during the maintenance phase and overall safety profile compared to vedolizumab.
650    _2
$a dospělí $7 D000328
650    _2
$a humanizované monoklonální protilátky $7 D061067
650    12
$a ulcerózní kolitida $x chemicky indukované $x farmakoterapie $7 D003093
650    12
$a Crohnova nemoc $x chemicky indukované $x farmakoterapie $7 D003424
650    _2
$a gastrointestinální látky $x škodlivé účinky $7 D005765
650    _2
$a lidé $7 D006801
650    12
$a idiopatické střevní záněty $x chemicky indukované $x farmakoterapie $7 D015212
650    _2
$a infliximab $x škodlivé účinky $7 D000069285
655    _2
$a časopisecké články $7 D016428
655    _2
$a metaanalýza $7 D017418
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Arkkila, Perttu $u Department of Gastroenterology, Helsinki University and Helsinki University Hospital, Helsinki, Finland
700    1_
$a Armuzzi, Alessandro $u Humanitas Research Hospital, Milan, Rozzano, Italy
700    1_
$a Danese, Silvio $u Gastroenterology and Endoscopy, University Vita-Salute San Raffaele, Milan, Italy
700    1_
$a Guardiola, Jordi $u Digestive Diseases Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain
700    1_
$a Jahnsen, Jørgen $u Department of Gastroenterology, Institute of Clinical Medicine, Akershus University Hospital, University of Oslo, Oslo, Norway
700    1_
$a Lees, Charles $u Center of Genomics and Experimental Medicine, University of Edinburgh, Edinburgh, UK
700    1_
$a Louis, Edouard $u Department of Gastroenterology, University Hospital CHU of Liège, Liège, Belgium
700    1_
$a Lukáš, Milan $u ISCARE Clinical Centre, Prague, Czech Republic
700    1_
$a Reinisch, Walter $u Medical University of Vienna, Vienna, Austria
700    1_
$a Roblin, Xavier $u University Hospital of Saint-Etienne, Saint-Etienne, France
700    1_
$a Jang, Minyoung $u Celltrion Healthcare, Incheon, Republic of Korea
700    1_
$a Byun, Han Geul $u Celltrion Healthcare, Incheon, Republic of Korea
700    1_
$a Kim, Dong-Hyeon $u Celltrion Healthcare, Incheon, Republic of Korea
700    1_
$a Lee, Sung Jeong $u Celltrion Healthcare, Incheon, Republic of Korea
700    1_
$a Atreya, Raja $u Medical Department 1, University Hospital Erlangen, Friedrich-Alexander-University of Erlangen-Nürnberg, Ulmenweg 18, 91054, Erlangen, Germany. raja.atreya@uk-erlangen.de $1 https://orcid.org/0000000285568433
773    0_
$w MED00006914 $t BMC gastroenterology $x 1471-230X $g Roč. 22, č. 1 (2022), s. 291
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35676620 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134516 $b ABA008
999    __
$a ok $b bmc $g 1821891 $s 1169280
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 22 $c 1 $d 291 $e 20220608 $i 1471-230X $m BMC gastroenterology $n BMC Gastroenterol $x MED00006914
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace